NAV

VidPrevtyn Beta

Identification

Summary

VidPrevtyn Beta is a recombinant, adjuvanted DNA vaccine given as a booster dose to prevent COVID-19.

Generic Name
VidPrevtyn Beta
DrugBank Accession Number
DB16427
Background

VidPrevtyn Beta is an adjuvanted, recombinant COVID-19 vaccine developed collaboratively by GlaxoSmithKline (GSK) and Sanofi Pasteur.3 It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from Sf9 cells of the fall armyworm, Spodoptera frugiperda - combined with GSK's AS03 adjuvant.1,4

In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.3

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Recombinant
Synonyms
  • COVID-19 Vaccine (recombinant, adjuvanted)
  • SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
External IDs
  • SP 0253
  • SP-0253
  • SP0253
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

VidPrevtyn Beta is indicated as a booster dose to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine.4

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Prevention ofCoronavirus disease 2019 (covid‑19)••••••••••••••••••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Compared to tozinameran, VidPrevtyn Beta demonstrated superiority in geometric mean titers (GMT) against Omicron BA.1 and non-inferiority of seroresponse rate against Omicron BA.1 and D614G strains, defined as a 4-fold or greater rise in serum neutralisation titre 28 days post- booster dose relative to pre-booster dose.4

Mechanism of action

The antigenic component of VidPrevtyn Beta is a soluble trimeric SARS-CoV-2 recombinant spike protein (B.1.351 strain) stabilized in its prefusion conformation and deleted of its transmembrane and intracellular domains.4,5 It is combined with an adjuvant, AS03, that serves to enhance the immune response.4,5 Administered intramuscularly, VidPrevtyn Beta elicits an active immune response that provides protection against COVID-19 caused by SARS-CoV-2.4

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
  • Humans

Chemical Identifiers

UNII
Not Available
CAS number
Not Available

References

General References
  1. Garcon N, Vaughn DW, Didierlaurent AM: Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil-in-water emulsion. Expert Rev Vaccines. 2012 Mar;11(3):349-66. doi: 10.1586/erv.11.192. [Article]
  2. Sanofi: Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly [Link]
  3. Sanofi Press Release: Press Release: Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn® Beta approved by the European Commission [Link]
  4. EMA Summary of Product Characteristics: VidPrevtyn Beta (COVID-19 vaccine, recombinant, adjuvanted) for intramuscular injection [Link]
  5. EMA Public Assessment Report: VidPrevtyn Beta [Link]
Wikipedia
COVID-19_vaccine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Liquid
Experimental Properties
Not Available

Drug created at January 13, 2021 20:11 / Updated at January 20, 2024 14:03